Fundamental Analysis of CORVUS PHARMACEUTICALS INC(NASDAQ:CRVS) stock

Fundamental Rating

Taking everything into account, CRVS scores 2 out of 10 in our fundamental rating. CRVS was compared to 588 industry peers in the Biotechnology industry. While CRVS seems to be doing ok healthwise, there are quite some concerns on its profitability. CRVS has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year CRVS has reported negative net income.

In the past year CRVS has reported a negative cash flow from operations.

In the past 5 years CRVS always reported negative net income.

CRVS had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -59.32%, CRVS perfoms like the industry average, outperforming 41.47% of the companies in the same industry.

CRVS has a Return On Equity (-69.86%) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
ROA	-59.32%
ROE	-69.86%
ROIC	N/A

ROA(3y)-53.13%

ROA(5y)-44.45%

ROE(3y)-62.66%

ROE(5y)-52.39%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CRVS so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, CRVS has more shares outstanding

CRVS has more shares outstanding than it did 5 years ago.

CRVS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -4.02, we must say that CRVS is in the distress zone and has some risk of bankruptcy.

The Altman-Z score of CRVS (-4.02) is worse than 60.92% of its industry peers.

There is no outstanding debt for CRVS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-4.02

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

CRVS has a Current Ratio of 4.07. This indicates that CRVS is financially healthy and has no problem in meeting its short term obligations.

With a Current ratio value of 4.07, CRVS perfoms like the industry average, outperforming 45.39% of the companies in the same industry.

A Quick Ratio of 4.07 indicates that CRVS has no problem at all paying its short term obligations.

With a Quick ratio value of 4.07, CRVS perfoms like the industry average, outperforming 46.42% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	4.07
Quick Ratio	4.07

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 35.96% over the past year.

EPS 1Y (TTM)35.96%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q33.33%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2QN/A

3.2 Future

CRVS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.39% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y1.58%

EPS Next 2Y-17.38%

EPS Next 3Y-13.17%

EPS Next 5Y13.39%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CRVS. In the last year negative earnings were reported.

Also next year CRVS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

CRVS's earnings are expected to decrease with -13.17% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-17.38%

EPS Next 3Y-13.17%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for CRVS!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CORVUS PHARMACEUTICALS INC

NASDAQ:CRVS (5/3/2024, 7:00:01 PM)

After market: 2.05 +0.13 (+6.77%)

1.92

+0.19 (+10.98%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap94.16M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-59.32%
ROE	-69.86%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	4.07
Quick Ratio	4.07
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)35.96%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y1.58%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

CORVUS PHARMACEUTICALS INC (CRVS)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens